Biotech Values

[ghmm]

I didn't care for it too much but non-UTHR investors may get a laugh (or shock) out of hearing Dr. Rothblatt's first eer sounds (I'll leave it at that) from the tadalafil approval.

http://ir.unither.com/eventdetail.cfm?eventid=69179

1 billion by 2013 is very doable (even with Oral)
150-200 for Adcirca
400-600 sub-q and IV (I am not sure on the impact of inhaled and some of the flolan generics seem more convenient)
400++ for Tyvaso

One thing about Tyvaso in EU they are going the centralized filing route which should (hopefully) make approval a lot easier then the fiasco they are undergoing now. They still get EU sales now under named patients but I expected they would have a flat out approval a couple years ago actually! The company has stated Germany Inhaled prostacylin is widely used.

There is an outside chance they get "lucky" on another indication that really boosts the outlook (e.g. Critical limb ischemia - oral or IPF - inhaled)